Compare RVP & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVP | KTTA |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 18.1M |
| IPO Year | 2000 | N/A |
| Metric | RVP | KTTA |
|---|---|---|
| Price | $0.67 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 16.2K | ★ 593.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,266,211.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.78 | N/A |
| 52 Week Low | $0.60 | $0.28 |
| 52 Week High | $1.14 | $2.06 |
| Indicator | RVP | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 33.23 |
| Support Level | $0.66 | $0.28 |
| Resistance Level | $0.74 | $0.52 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.77 | 6.47 |
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.